TauRx Pharmaceutics
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
April 10, 2025Research and Development Alzheimer's disease, Neurology, TauRx Pharmaceutics, research and development
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the progression of Alzheimer’s disease over …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
